68

Jiangsu Cowin Biotech Co. Ltd. A

688426 · SHG · Healthcare / Biotechnology

18.10CNY-0.63 (-3.36%)

Price History

Full chart

Market Stats

Previous Close18.73
Open17.25
Day Range17.25 – 18.99
52-Week Range14.42 – 33.67
Volume991.74K
Market Cap2.54B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.79
Dividend Yield0.00%
Beta0.79
50-Day Avg19.81
200-Day Avg21.18

About

Jiangsu CoWin Biotech Co., Ltd. engages in the research, development, sales, testing, and technology services of biological reagents in China. The company offers RT-PCR, PCR, multiplex PCR, and qPCR; collection, such as cfDNA, fecal DNA, saliva DNA, and urine DNA storage tube, as well as other collection products; cfDNA, genomic DNA, FFPE DNA extraction, and plasmid kit; molecular raw materials; quantitative analysis, RNA sequencing, adapter, purification magbeads, DNA sequencing, and single cells sequencing products; molecular cloning, such as cloning reagents; nucleic acid residue and contamination screening reagent; and other products. It also provides gene synthesis, gene fragment, and codon optimization services. The company's products and services are used in infectious disease, eugenics and good parenting, and oncology applications. The company was founded in 2007 and is headquartered in Taizhou, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Chun Xiang Wang
  • Employees732
  • HeadquartersNo. 18, Zelan Road, Taizhou, China, 225311, China
  • Websitehttps://www.cwbio.com

Leadership

  • Dr. Chun Xiang WangGM & Chairman · b. 1967
  • Ms. Zhihua ZhuangDeputy GM & Director · b. 1981
  • Mr. Yubai QiDeputy GM, Board Secretary & Director · b. 1981

Financials

Income Statement

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue233.21M338.46M521.60M171.34M125.88M193.52M
Growth (%)-+45.13%+54.11%-67.15%-26.54%+53.74%
Cost of Revenue53.25M93.63M156.96M60.61M55.48M105.65M
Gross Profit179.97M244.83M364.64M110.73M70.40M87.87M
Gross Margin77.17%72.34%69.91%64.62%55.93%45.41%
Operating Expense54.87M103.21M169.57M215.98M226.40M208.24M
Operating Income125.10M141.62M195.08M-105.25M-156.00M-120.36M
Operating Margin53.64%41.84%37.40%-61.43%-123.93%-62.20%
EBITDA--220.58M-57.74M-124.22M-71.02M
EBITDA Margin--42.29%-33.70%-98.68%-36.70%
Net Income108.16M125.85M159.26M-84.41M-157.21M-107.41M
Net Income Margin46.38%37.18%30.53%-49.26%-124.89%-55.50%
R&D23.76M38.58M74.02M88.26M99.23M77.37M
R&D as % of Total Revenue10.19%11.40%14.19%51.51%78.84%39.98%
Interest Expense116.62K1.92M1.93M1.70M1.39M966.06K
Interest Expense % of Total Revenue0.05%0.57%0.37%0.99%1.11%0.50%

Balance Sheet

Currency: CNY2020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets471.60M648.77M1.96B1.82B1.62B1.50B
Total Liabilities57.04M100.51M163.60M142.67M131.79M138.47M
Total Equity414.00M548.26M1.78B1.66B1.47B1.35B
Cash38.84M127.82M1.03B348.34M255.47M161.28M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-108.89M144.50M107.37M-11.72M-113.26M-58.99M
Capital Expenditure013.46M124.39M100.38M159.22M48.41M34.82M
Free Cash Flow-95.44M20.11M6.99M-170.94M-161.67M-93.82M
Dividends Paid138.98K32.58M--50.73M3.90M257.44K
FCF to OCF-87.64%13.92%6.51%1458.16%142.74%159.03%
Dividend Paid to FCF-34.13%---29.68%-2.41%-0.27%

Earnings

Report DateMar 31, 2023
EPS Estimate-
EPS Actual0.04
Surprise-
Timing-

Key Statistics & Ratios

Market Cap2.54B
Enterprise Value1.96B
Trailing P/E0.00
Forward P/E0.00
Price / Sales11.58
Price / Book2.03
EPS-0.79
Book Value11.99
Revenue (TTM)219.42M
Gross Profit (TTM)92.27M
EBITDA-79.87M
Profit Margin-39.51%
Operating Margin-50.04%
Return on Equity-6.57%
Return on Assets-4.47%
Shares Outstanding112.49M
Shares Float34.91M
Beta0.79
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
0.52Jun 12, 2023

Stock Splits

  • Jun 12, 20231.2:1